Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERA006 NBMI in PSP or MSA
2018-000506-34Phase 2Completed
- Sponsor
- EmeraMed
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emeramide in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) (2 arms), sponsored by EmeraMed. Primary endpoint: Change from baseline in motor symptoms, non-motor symptoms, and health-related quality of life versus placebo. Started Mar 2018; status: completed.
02
Drugs
emeramide
03
Conditions
progressive supranuclear palsy (PSP)multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2018-000506-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000506-34.